Chimerix (NASDAQ:CMRX) Research Coverage Started at StockNews.com

StockNews.com started coverage on shares of Chimerix (NASDAQ:CMRX) in a research report report published on Sunday morning. The firm issued a sell rating on the biopharmaceutical company’s stock.

CMRX has been the topic of several other research reports. Wedbush reaffirmed a “neutral” rating and set a $8.55 price target (up previously from $7.00) on shares of Chimerix in a report on Wednesday, March 5th. Jefferies Financial Group reaffirmed a “hold” rating and set a $8.50 price target (down previously from $10.00) on shares of Chimerix in a research note on Wednesday, March 5th. Finally, HC Wainwright reiterated a “neutral” rating and set a $8.55 price objective (down previously from $11.00) on shares of Chimerix in a research report on Wednesday, March 5th.

Chimerix Stock Performance

Shares of Chimerix stock opened at $8.54 on Friday. The company’s fifty day simple moving average is $8.52 and its two-hundred day simple moving average is $5.16. The company has a market cap of $801.09 million, a P/E ratio of -9.09 and a beta of -0.17. Chimerix has a 12-month low of $0.75 and a 12-month high of $8.55.

Chimerix (NASDAQ:CMRX) last announced its quarterly earnings data on Friday, March 21st. The biopharmaceutical company reported ($0.25) EPS for the quarter, beating the consensus estimate of ($0.26) by $0.01. The firm had revenue of $0.06 million for the quarter, compared to analysts’ expectations of $0.31 million. Analysts predict that Chimerix will post -0.99 EPS for the current fiscal year.

Institutional Trading of Chimerix

Large investors have recently made changes to their positions in the business. PenderFund Capital Management Ltd. purchased a new stake in shares of Chimerix in the 1st quarter valued at $35,000. Longfellow Investment Management Co. LLC purchased a new stake in shares of Chimerix in the 1st quarter valued at $74,000. Bender Robert & Associates purchased a new stake in shares of Chimerix in the 4th quarter valued at $37,000. Twin Tree Management LP purchased a new stake in shares of Chimerix in the 1st quarter valued at $100,000. Finally, Susquehanna Fundamental Investments LLC purchased a new stake in shares of Chimerix in the 4th quarter valued at $59,000. 45.42% of the stock is owned by hedge funds and other institutional investors.

Chimerix Company Profile

Chimerix, Inc, a biopharmaceutical company, develops medicines to improve and extend the lives of patients facing deadly diseases. Its pipeline products include ONC201 a program that is in Phase 3 clinical trial for treating patients with H3 K27M-mutant diffuse glioma, as well as in Phase 2 clinical trial for the treatment of rare neuroendocrine tumors; and ONC206, an imipridone, Dopamine Receptor D2 (DRD2) antagonist, and caseinolytic protease P (ClpP) agonist, which is in Phase 1 clinical trial for adult and pediatric patients with primary central nervous system tumors.